Migraine Market

• The total Migraine market size in the 7MM was approximately USD 10,880 million in 2023 and is projected to increase during the forecast period (2024-2034).
• In 2023, the market size of Migraine was highest in the US among the 7MM accounting for approximately USD 6,790 million that is further expected to increase by 2034.
• Migraine prevalence is expected to rise, driven by factors including heightened awareness, lifestyle changes, environmental influences, genetic predisposition, an aging population, hormonal fluctuations, technological advancements, and psychological stressors. Addressing this trend requires multifaceted strategies across healthcare, research, and public policy domains.
• In 2023, the US accounted for the maximum patient share of Migraine in the 7MM, i.e., 39%, followed by Japan accounting for around 14% of the total 7MM cases. Among the European countries higher number of cases were in the UK accounting for about 11% of the total 7MM cases.
• In February 2025, the FDA cleared a migraine device for children as young as eight years old, expanding its use beyond adults and offering new hope for young migraine sufferers.
• In January 2025, the FDA approved Axsome Therapeutics’ AXS-07, an oral, rapidly absorbed, multi-mechanistic agent, as a new acute treatment for migraine with or without aura in adults. Marketed as Symbravo, the company expects AXS-07 to be commercially available in the U.S. in about four months, following the FDA's acceptance of its NDA resubmission in September 2024.
• In December 2024, ShiraTronics announced the initiation of its FDA investigational device exemption (IDE) pivotal trial for its neuromodulation therapy. The RELIEV-CM2 clinical study will evaluate the therapy for chronic migraine, with the first implants completed in the U.S. and Australia. The study aims to assess the long-term safety and efficacy of the system. In October, the company raised $66 million to support the trial's launch.
• In November 14, 2024, Theranica announced that the FDA has expanded the age indication for its Nerivio® REN wearable to include patients aged 8 and above. This makes Nerivio the first FDA-cleared, non-drug therapy for acute migraine treatment in children. It is also the only prescribed preventive migraine treatment for this age group.

Request for unlocking the CAGR of the Migraine Drugs Market

DelveInsight's “Migraine Market Insights, Epidemiology and Market Forecast– 2034” report delivers an in-depth understanding of the Migraine, historical and forecasted epidemiology as well as the Migraine therapeutics market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Migraine market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Migraine market size from 2020 to 2034. The report also covers current Migraine treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Migraine Treatment Market

Migraine Overview

Migraine, a complex neurological disorder, encompasses several types, including migraine without aura, migraine with aura, and chronic migraine. Common symptoms include throbbing head pain, nausea, vomiting, and sensitivity to light and sound. The exact causes are multifactorial, involving genetic predisposition, environmental triggers, hormonal fluctuations, and neurological dysfunction. Migraine can be classified based on how frequently the attacks occur in two types. Episodic migraine occurs less than 15 days/month, while chronic migraine happens on 15 or more days/month for at least three months. Chronic migraine imposes greater burden and requires comprehensive management. Migraine imposes a significant disease burden, affecting individuals' quality of life, productivity, and mental health.

Migraine Diagnosis

Diagnosing migraine relies on evaluating symptoms, medical history, and ruling out other conditions. Challenges include the variability of symptoms, lack of specific diagnostic tests, and overlapping features with other disorders, leading to under recognition and misdiagnosis. Additionally, migraine is often underreported due to stigma or normalization of symptoms, hindering timely intervention. Improved awareness among healthcare providers and the general public, coupled with the development of more precise diagnostic tools, can help address these diagnostic challenges and ensure appropriate management of migraine.

Further details related to country-based variations are provided in the report...

Migraine Treatment

The primary goals of migraine treatment have traditionally included relieving pain, restoring function, and reducing headache frequency. An additional goal may be preventing the progression of episodic migraine to chronic migraine. Optimal treatment also encompasses the management of comorbidities. Treatment decisions are based on the type of migraine (episodic or chronic), the level of impairment they cause, previous treatment history, and patient preferences. In addition, clinicians must consider comorbid conditions and the potential for drug interactions with existing medications during treatment selection. Treatment strategies include educational interventions, lifestyle modifications, trigger management, and acute and preventive pharmacotherapy. Not every patient with episodic migraine needs prevention, but every patient with chronic migraine needs prevention.

Migraine Epidemiology

As the market is derived using the patient-based model, the Migraine epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by, Prevalence of Migraine, Prevalent Cases of Migraine by Severity, Gender-specific Prevalent Cases of Migraine, and Diagnosed Cases of Episodic and Chronic Migraine in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

• In 2023, the prevalent population of Migraine in the 7MM was found to be ~119,233 cases.
• The total prevalent cases of Migraine in the US are expected to increase with a significant CAGR by 2034, from around 46,140k cases in 2023 in the US.
• Among the European countries, Germany (22%) had the highest prevalent population of Migraine, followed by Italy in 2023. On the other hand, Spain had the least prevalent population around 17% of Migraine in the same year.
• However, the prevalent cases of Migraine are expected to decrease in Germany and Japan attributed to decrease in country population and other factors.
• In Japan, among prevalent cases of Migraine, most cases were of Episodic Migraine (~16,331k) in 2023. While least were in Chronic Migraine around ~950k  in the same year.
• Assessments as per DelveInsight’s analysts show that the majority of cases of Migraine are occupied by females in comparison to males. There were approximately ~11,535k male and ~34,605k female cases of Migraine in 2023 in the US.
• In EU4 and the UK, among diagnosed cases of Migraine, most cases were of Episodic Migraine (~15,839k) in 2023. While least were in Chronic Migraine around ~2,411k in the same year.

Unlock comprehensive insights! Click Here to Purchase the Full Epidemiology Report @ Migraine Prevalence

Migraine Recent Developments

• In September 2025, ShiraTronics reported promising 12-month results from its RELIEV-CM Pilot Study, showing sustained reductions in headache frequency and severity in patients with chronic migraine. The data support the long-term safety and effectiveness of its fully implantable Migraine Therapy System, a novel neuromodulation device.
• In August 2025, the FDA approved Teva’s AJOVY (fremanezumab-vfrm) for the preventive treatment of episodic migraine in pediatric patients aged 6–17 years weighing at least 45 kg, making it the first and only CGRP antagonist approved for migraine prevention in both children and adults.
• In May 2025, shares of Amneal Pharmaceuticals (AMRX) rose slightly after the FDA approved its Brekiya autoinjector for treating migraines and cluster headaches in adults. The device enables self-administration of dihydroergotamine (DHE), typically given intravenously in clinical settings.
• In May 2025, Amneal Pharmaceuticals (Nasdaq: AMRX) announced FDA approval of Brekiya® (dihydroergotamine mesylate) autoinjector for the acute treatment of migraine with or without aura and cluster headaches in adults. Brekiya is the first and only DHE autoinjector, offering hospital-grade medication in a convenient, ready-to-use, self-administered device that requires no refrigeration or assembly. It provides sustained pain relief and may benefit patients who cannot tolerate or respond poorly to oral migraine therapies.
• In April 2025, Satsuma Pharmaceuticals, Inc. and its parent company, Shin Nippon Biomedical Laboratories, announced that the FDA approved the 505(b)(2) NDA for Atzumi™ (dihydroergotamine nasal powder) for the acute treatment of migraine with or without aura in adults. Atzumi was previously known as STS101.
• In April 2025, Click Therapeutics received FDA marketing authorization for CT-132, the first prescription digital therapeutic for the preventive treatment of episodic migraine in patients aged 18 and older. The therapy is intended for adjunctive use with acute and other preventive treatments for migraine.
• In February 2025, the FDA cleared a migraine device for children as young as eight years old, expanding its use beyond adults and offering new hope for young migraine sufferers.
• In January 2025, the FDA approved Axsome Therapeutics’ AXS-07, an oral, rapidly absorbed, multi-mechanistic agent, as a new acute treatment for migraine with or without aura in adults. Marketed as Symbravo, the company expects AXS-07 to be commercially available in the U.S. in about four months, following the FDA's acceptance of its NDA resubmission in September 2024.
• In November 2024, Theranica announced that the FDA has expanded the age indication for its Nerivio® REN wearable to include patients aged 8 and above. This makes Nerivio the first FDA-cleared, non-drug therapy for acute migraine treatment in children. It is also the only prescribed preventive migraine treatment for this age group.

Migraine Drug Chapters

The drug chapter segment of the Migraine report encloses a detailed analysis of Migraine marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Migraine clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Migraine Marketed Drugs

EMGALITY (Galcanezumab-gnlm): Eli Lilly and Company

EMGALITY (Galcanezumab-gnlm) is a humanized IgG4 monoclonal antibody specific for calcitonin-gene-related peptide (CGRP) ligand. EMGALITY is a calcitonin-gene-related peptide antagonist indicated in adults for the preventive treatment of migraine and the treatment of episodic cluster headache. FDA approved EMGALITY in September 2019 for preventing migraine in adults, but it's contraindicated for those hypersensitive to galcanezumab-gnlm or its components. In November 2019, the EU approved galcanezumab for adults with ≥4 migraine days/month.

Get More Insights @ EMGALITY Market

AJOVY (fremanezumab-vfrm): Teva Pharmaceuticals

AJOVY (Fremanezumab-vfrm) is a fully monoclonal antibody specific for calcitonin gene-related peptide (CGRP) ligand. In September 2019, the FDA sanctioned AJOVY for adult migraine prevention. By January 2020, an autoinjector for Fremanezumab received FDA approval. In March 2019, AJOVY earned European Commission approval for adult migraine prophylaxis. Teva's AJOVY gained approval in Japan in June 2021.

Know More Insights @ AJOVY Market

Note: Detailed current therapies assessment will be provided in the full report of Migraine...

Migraine Emerging Drugs

AXS-07: Axsome Therapeutics

AXS-07 is a novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine. AXS-07 consists of MoSEIC (Molecular Solubility Enhanced Inclusion Complex) meloxicam and rizatriptan. AXS-07 is thought to act by inhibiting Calcitonin gene-related peptide (CGRP) release, reversing CGRP-mediated vasodilation, and inhibiting neuroinflammation, pain signal transmission, and central sensitization Meloxicam is a new molecular entity for migraine enabled by MoSEIC technology, which results in rapid absorption of meloxicam while maintaining a long plasma half-life. AXS-07 is an investigational drug not approved by the FDA and its safety and effectiveness have not been established. AXS-07 is currently being developed for the acute treatment of migraine. The product is in the NDA phase of development.

Discover the future of Migraine treatments! Explore emerging therapies and key players in the Migraine Pipeline Insight, 2025! 

Migraine Drug Class Insights

Advances in migraine understanding have refined diagnosis and treatment into acute (triptans, NSAIDs, opioids) and preventive therapy (propranolol, botox). Triptans predominate acute treatment due to efficacy and availability, followed by NSAIDs and analgesics. Preventive options include FDA-approved agents like propranolol, timolol, divalproex sodium, OnabotulinumtoxinA (botox) and topiramate; other agents possess established efficacy but lack FDA approval. These therapies have been allocated into the following therapeutic classes in the forecast estimates: antiepileptics, antihypertensives, antihypertensives and neurotoxins.

Migraine Market Outlook

Migraine is a common neurologic disorder characterized by attacks consisting of throbbing, unilateral headache accompanied by photophobia, phonophobia and nausea, which remarkably reduces the patients’ quality-of-life (QoL). It is a leading cause of disability and suffering worldwide and was ranked as the second cause of years lost due to disability globally in 2019.

There has been a significant advancement in understanding migraine pathophysiology, which has led to the improved characterization and diagnosis of the clinical features. The existing treatment scenario can be primarily divided into acute/abortive and preventive. Acute treatment is initiated during an attack to alleviate pain and disability and stop the attack’s progression. Preventive treatment is used when there is a known headache trigger, such as exercise or sexual activity, and for patients who have limited time exposure to a trigger, such as high-altitude ascent or menstruation.

The primary revenue-generating components of the acute treatment market can be classified broadly into the following therapeutic classes, namely triptans, NSAIDs, analgesics/opioids and DHE (dihydroergotamine) or ergot alkaloids. Triptans continue to dominate the overall acute treatment landscape generating the highest amount of revenue. Some of the major drugs (generics/branded) belonging to this class are eletriptan, almotriptan, sumatriptan, rizatriptan, zolmitriptan and few others. Triptans are usually preferred over DHE because of the wider availability of dosage forms, tolerability, adverse effect profile, and better efficacy. Acetaminophen, aspirin, and NSAIDs are mostly used for mild-to-moderate attacks. They constitute the next significant class of molecules that leave a considerable impact on the firmament.

Preventive/prophylactic therapy is used to reduce the frequency, severity, and duration of migraine attacks, as already stated in the previous sections. The FDA approved preventive migraine agents include propranolol, timolol, divalproex sodium, OnabotulinumtoxinA (botox) and topiramate; other agents possess established efficacy but lack FDA approval. These therapies have been allocated into the following therapeutic classes in the forecast estimates: antiepileptics, antihypertensives, antihypertensives and neurotoxins. Botox is the only non-daily injectable preventive therapy, has far fewer side effects than daily oral agents and is the only therapy specifically approved for CM.

The race to dominate the unclaimed territory has received momentum with the identification of two major biomarkers acting as potential treatment targets, namely serotonin 1F (5-HT1F) receptor and calcitonin gene-related peptide (CGRP).

The year 2019 marked a watershed moment when three CGRP mAbs were FDA approved for the prevention of migraines in adults: Novartis/Amgen’s Aimovig (erenumab), Teva’s Ajovy (fremanezumab), and Eli Lilly’s Emgality (galcanezumab). Not only did these products become the first migraine-specific drugs approved for migraine prevention, but they marked the first novel entrants to the prevention market since the expanded labeling of Botox for chronic migraine in 2010.

It is important to note that there are various newer novel therapies for the treatment of Migraine in the pipeline.

• The total market size of Migraine in the 7MM was approximately USD 10,880 million in 2023 and is projected to increase during the forecast period (2024-2034).
• The market size in the 7MM will increase at a constant CAGR due to increasing awareness of the disease, better diagnosis, and the launch of the emerging target therapy for Migraine.
• Among EU4 and the UK, Germany with a share of 25% accounted for the maximum market size in 2023 while the UK occupied the bottom of the ladder with a share of 14% in 2023.
• In 2023, Japan had a share, approximately 6%, of the Migraine treatment market among the seven major markets (7MM).
• In 2023, the market size of episodic migraine (preventive + acute) was around USD 4,026 million in the US, while that for chronic migraine (preventive + acute) was nearly USD 2,766  million in the same year.

Migraine Drugs Uptake

This section focuses on the rate of uptake of the potential drugs expected to get launched in the market during the study period 2020-2034. For example, for CS1, we expect the drug uptake to be medium with a probability-adjusted peak share of around 4.2%, and years to the peak is expected to be 4 years from the year of launch in the US.

Further detailed analysis of emerging therapies drug uptake in the report...

Migraine Pipeline Development Activities

The report provides insights into different Migraine clinical trials within Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions and mergers, licensing, and patent details for Migraine emerging therapies.

Take Your Research to the Next Level! Click Here to Get Access to the Full Pipeline Report @ New Migraine Drugs

KOL- Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on Migraine evolving treatment landscape, patient reliance on conventional therapies, patient’s therapy switching acceptability, and drug uptake along with challenges related to accessibility, include University of California at San Francisco, San Francisco, CA, USA; Neurology Department, Montpellier University Hospital, Montpellier, France; Sant'Andrea University Hospital, Rome, Italy; Department of Neurology Headache Center, Tominaga Hospital, Osaka, Japan, and others.

Delveinsight’s analysts connected with 50+ KOLs to gather insights, however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or Migraine market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis, and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis is done to analyze multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Reimbursement is a crucial point for any drug after its approval. Many drugs or therapies are not properly recognized by the reimbursement body and may fail to get reimbursed or their reimbursement process gets delayed.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Migraine Market Report

• The report covers a segment of key events, an executive summary, descriptive overview of Migraine, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression along with treatment guidelines
• Additionally, an all-inclusive account of both the current and emerging therapies along with the elaborative profiles of late-stage and prominent therapies will have an impact on the current treatment landscape
• A detailed review of the Migraine market; historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preference that help in shaping and driving the 7MM Migraine market

Migraine Report Insights

• Patient Population
• Therapeutic Approaches
• Migraine Pipeline Analysis
• Migraine Market Size and Trends
• Existing and future Market Opportunity

Migraine Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Migraine Epidemiology Segmentation
• Key Cross Competition
• Attribute analysis
• Drugs Uptake and Key Market Forecast Assumptions

Migraine Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions Answered In The Migraine Market Report

Migraine Market Insights:

• What was the Migraine total market size, the market size by therapies, and market share (%) distribution in 2020, and how it would all look in 2034? What are the contributing factors for this growth?
• What are the unmet needs are associated with the current treatment market of Migraine?
• How is AXS-07 going to contribute to the market of Migraine after approval?
• Which drug is going to be the largest contributor in 2034?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Migraine Epidemiology Insights:

• What are the disease risk, burden, and unmet needs of Migraine? What will be the growth opportunities across the 7MM concerning the patient population of Migraine?
• What is the historical and forecasted Migraine patient pool in the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan?
• Why do only limited patients appear for diagnosis? Why is the current year diagnosis rate not high?
• What factors are affecting the diagnosis and treatment of the indication?

Current Migraine Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the treatment of Migraine? What are the current treatment guidelines for the treatment of Migraine in the US and Europe?
• How many companies are developing therapies for the treatment of Migraine?
• How many emerging therapies are in the mid-stage and late stage of development for the treatment of Migraine?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the key designations that have been granted for the emerging therapies for Migraine?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.
• What are the 7MM historical and forecasted market of Migraine?

Reasons to buy Migraine Market Forecast Report

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Migraine Market
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the Conjoint analysis section to provide visibility around leading classes
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs
• To understand the perspective of Key Opinion Leaders’ around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in future
• Detailed insights on the unmet need of the existing market so that the upcoming players can strengthen their development and launch strategy

Read Out Recent Articles

• Migraine Market: Infographics
• Snippet: Migraine
• AXS-07 Shines at AAN 2024: A New Era in Migraine Treatment
• A New Era for Migraine Treatment and CGRP antibodies
• US approval to Lundbeck’s Vyepti for preventive migraine care; Esperion’s cholesterol-lowering drug Nexletol receives FDA nod; Karius – a start-up company – raises USD 165 Million – strengthens it liquid biopsy testing
• Migraine Market: How Pharma Companies are trying to Uncomplicate the Disease and Bring in Novel Therapies
• Neuromodulation Devices Observed to Reshape the Migraine Treatment Dynamics
• Latest DelveInsight Blogs